Search results for "Cognition disorders"

showing 10 items of 277 documents

Validation of a New Cognitive Screening Method for Stroke Patients

2019

Objective. Two million adults under fifty years of age have a cerebral stroke every year worldwide. Neuropsychological assessment is the best way to identify poststroke cognitive dysfunction, but it is often time-consuming and can be tiring for the patient, and hospitals vary in their availability of neuropsychological expertise. A valid and reliable cognitive screening method could be advantageous in identifying patients who need comprehensive neuropsychological examination. Our purpose in this study was to validate a newly developed cognitive screening method as an identifier of cognitive dysfunction after stroke in working-aged patients. Methods. We analyzed new cognitive screening metho…

MaleNeuropsychological TestsaivohalvauspotilaatCognition0302 clinical medicineMass ScreeningMedicine030212 general & internal medicineNeuropsychological assessmentCognitive declineStrokevalidationmedicine.diagnostic_testNeuropsychologyCognitionGeneral MedicineMiddle Agedkognitiiviset prosessitMental Status and Dementia TestsStrokeNeuropsychology and Physiological PsychologyNeurologyvalidointiFemaleRC321-571Research ArticleAdultmedicine.medical_specialtyPsychometricsArticle SubjecttoimintahäiriötConcurrent validityNeurosciences. Biological psychiatry. NeuropsychiatrySensitivity and Specificity03 medical and health sciencesCronbach's alphaHumansCognitive DysfunctionAgedseulontatutkimusReceiver operating characteristicbusiness.industryReproducibility of Resultsstroke patientsmedicine.diseasecognitive screening methodROC CurvePhysical therapyNeurology (clinical)Cognition Disordersbusiness030217 neurology & neurosurgeryBehavioural Neurology
researchProduct

SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging☆

2008

Statistical comparisons of [(18)F]FDG PET scans between healthy subjects and patients with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI) using Statistical Parametric Mapping (SPM) usually require normalization of regional tracer uptake via ROIs defined using additional software. Here, we validate a simple SPM-based method for count normalization. FDG PET scans of 21 mild, 15 very mild AD, 11 aMCI patients and 15 age-matched controls were analyzed. First, we obtained relative increases in the whole patient sample compared to controls (i.e. areas relatively preserved in patients) with proportional scaling to the cerebral global mean (CGM). Next, average absolute counts…

MaleNormalization (statistics)Agingmedicine.medical_specialtyPathologyCognitive NeuroscienceLogistic regressionStatistical parametric mappingNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Internal medicineImage Interpretation Computer-AssistedmedicineHumansDementiaHealthy agingRadionuclide ImagingCognitive impairmentAgedRetrospective StudiesBrain Mappingmedicine.diagnostic_testBrainmedicine.diseaseNeurologyPositron emission tomographyCardiologyFemaleCognition DisordersPsychologyAlgorithmsNeuroImage
researchProduct

Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18

2007

At present, there is still no consensus on the choice of the reference area in positron emission tomography (PET) studies of Alzheimer's disease (AD). In this study, PET scans with fluorodeoxyglucose-F18 were carried out in the following groups of subjects: 47 patients with probable AD, 8 patients with mild cognitive impairment, and 15 age-similar healthy subjects. Scans normalized to the cerebral global mean (CGM), cerebellum (CBL), and the primary sensorimotor cortex (SMC). We evaluated the effect of the different count normalization procedures on the accuracy of (18)F-FDG PET to detect AD-specific metabolic abnormalities (voxel-based group comparison) and to differentiate between patient…

MaleNormalization (statistics)Pathologymedicine.medical_specialtyAdolescentNeuroscience (miscellaneous)Neuropsychological TestsStatistical parametric mappingGyrus CinguliSeverity of Illness IndexCentral nervous system diseaseAlzheimer DiseaseFluorodeoxyglucose F18CerebellumParietal LobemedicineHumansDementiaRadiology Nuclear Medicine and imagingAgedFluorodeoxyglucosemedicine.diagnostic_testbusiness.industryCognitive disorderMotor CortexSomatosensory Cortexmedicine.diseaseTemporal LobeFrontal LobePsychiatry and Mental healthPositron emission tomographyPositron-Emission TomographyFemaleRadiopharmaceuticalsAlzheimer's diseaseCognition DisordersNuclear medicinebusinessPsychologymedicine.drugPsychiatry Research: Neuroimaging
researchProduct

Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease

2008

Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which results in a loss of kinase domain on the PINK1 protein (D297fsX318). This mutation was identified in two brothers with early-onset Parkinson disease (EOPD) from a Sicilian consanguineous family. Of note, while one of the two patients developed mental deterioration and psychiatric problems, the other showed no cognitive decline. The present study supports the view that PINK1 is a pathogenic gene in some Italian families with EOPD and contributes to define the PINK1-associated phenotype. Herein we first describe a novel homozygous single nucleotide deletion in PINK1 exon 4 (889delG) which r…

MaleParkinson's diseaseGenotypeParkinson's diseaseMolecular Sequence DataPINK1DiseaseBiologyAntiparkinson AgentsLevodopaExonmedicineHumansAmino Acid SequenceAge of OnsetCognitive declineGeneAgedGeneticsGenotype–phenotype correlationPINK1Parkinson DiseaseExonsFamilial formmedicine.diseasePhenotypePedigreeSettore BIO/18 - GeneticaPhenotypeNeurologyMutationMutation (genetic algorithm)Settore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyCognition DisordersProtein KinasesGene DeletionParkinsonism & Related Disorders
researchProduct

Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving…

2011

Abstract Background Conventional magnetic resonance imaging (MRI) has improved the diagnosis and monitoring of multiple sclerosis (MS). In clinical trials, MRI has been found to detect treatment effects with greater sensitivity than clinical measures; however, clinical and MRI outcomes tend to correlate poorly. Methods In this observational study, patients (n = 550; 18-50 years; relapsing-remitting MS [Expanded Disability Status Scale score ≤4.0]) receiving interferon (IFN) β-1a therapy (44 or 22 µg subcutaneously [sc] three times weekly [tiw]) underwent standardized MRI, neuropsychological and quality-of-life (QoL) assessments over 3 years. In this post hoc analysis, MRI outcomes and corre…

MalePathologyNeurologyDiseaseRelapsing-RemittingNeuropsychological Testslcsh:RC346-4290302 clinical medicineRelapsing-Remitting Multiple Sclerosi030212 general & internal medicine10. No inequalitymedicine.diagnostic_testBrainGeneral MedicineMagnetic Resonance Imaging3. Good healthFemaleSettore MED/26 - NeurologiaRadiologyNeurosurgeryMagnetic Resonance Imaging; Neuroimaging; Immunologic Factors; Dose-Response Relationship Drug; Humans; Brain; Interferon-beta; Quality of Life; Multiple Sclerosis Relapsing-Remitting; Cognition Disorders; Adult; Neuropsychological Tests; Female; MaleDrugInterferon beta-1aResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisClinical NeurologyNeuroimagingDose-Response Relationship03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingNeuroimagingmedicineImmunologic FactorsHumansNeurochemistrylcsh:Neurology. Diseases of the nervous systemDose-Response Relationship Drugbusiness.industryMultiple sclerosisMagnetic resonance imagingBrain Magnetic Resonance ImagingInterferon-betamedicine.diseaseClinical trialBrain Magnetic Resonance Imaging; Relapsing-Remitting Multiple Sclerosis; Interferon beta-1aQuality of LifeNeurology (clinical)businessCognition Disorders030217 neurology & neurosurgery
researchProduct

Ultrastructural Hippocampal and White Matter Alterations in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study

2003

Mild cognitive impairment (MCI) is considered to be a transitional stage between normal aging and dementia. In Alzheimer’s disease (AD), white matter structural pathology is due to Wallerian degeneration and central angiopathy. However, in MCI patients, the presence and extent of white matter alterations as a possible correlate of impaired memory function and as predictor of subsequent progression to AD is not clarified yet. Diffusion tensor imaging (DTI) reveals the ultrastructural integrity of cerebral white matter tracts. Therefore, it could detect pathological processes that modify tissue integrity in patients with MCI. In our prospective study, conventional and diffusion tensor MR scan…

MalePathologymedicine.medical_specialtyCognitive NeuroscienceHypercholesterolemiaSpleniumHippocampusNeuropsychological TestsCorpus callosumHippocampusWhite matterAlzheimer DiseaseRisk Factorsmental disordersFractional anisotropyCentrum semiovaleImage Processing Computer-AssistedmedicineHumansAgedPsychiatric Status Rating Scalesmedicine.diagnostic_testBrainMagnetic resonance imagingMagnetic Resonance ImagingPsychiatry and Mental healthmedicine.anatomical_structureHypertensionAnisotropyFemaleGeriatrics and GerontologyCognition DisordersPsychologyDiffusion MRIDementia and Geriatric Cognitive Disorders
researchProduct

Association of elevated phospho-tau levels with alzheimer-typical 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography findings in patients with…

2003

Abstract Background Mild cognitive impairment is considered to be a transitional stage between normal aging and dementia. Phosphorylated tau protein in cerebrospinal fluid and even more decrements of cerebral glucose metabolism in parietal, temporal, or cingulate regions have shown favorable specificity for the diagnosis of Alzheimer dementia and could be useful supplementary tools to determine Alzheimer pathology in early stages. Methods We measured cerebrospinal fluid tau phosphorylated at threonine 181 protein, cerebrospinal fluid total tau, and cerebral glucose metabolism using 18F-fluoro-2-deoxy-D-glucose positron emission tomography in 16 patients with mild cognitive impairment and ag…

MalePathologymedicine.medical_specialtyTau proteintau ProteinsNeuropsychological TestsStatistics NonparametricCentral nervous system diseasechemistry.chemical_compoundCerebrospinal fluidAlzheimer DiseaseFluorodeoxyglucose F18Predictive Value of Testsmental disordersmedicineHumansDementiaPhosphorylationBiological PsychiatryAgedAged 80 and overBrain ChemistryBrain Mappingmedicine.diagnostic_testbiologybusiness.industryMiddle Agedmedicine.diseaseGlucosechemistryPositron emission tomographyCase-Control Studiesbiology.proteinBiomarker (medicine)FemaleAlzheimer's diseaseCognition Disorders2-Deoxy-D-glucosebusinessTomography Emission-ComputedBiological Psychiatry
researchProduct

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results…

2009

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results…

MalePediatricsIntelligenceRelapsing-RemittingNeuropsychological TestsSeverity of Illness IndexDisability EvaluationCognitionRisk FactorsOdds RatioPrevalenceNeuropsychological assessmentProspective StudiesNeurologic Examinationmedicine.diagnostic_testCognitive impairmet. Cognitive function. Multiple Sclerosis. Neuropsychological assessment.Cognitive disorderNeuropsychologyAge FactorsMiddle AgedMagnetic Resonance ImagingCognitive testTreatment OutcomeNeurologyItalyFemaleSettore MED/26 - NeurologiaPsychologyAdultmedicine.medical_specialtyMultiple SclerosisAdolescentNeurological examinationRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsMagnetic Resonance Imaging; Young Adult; Age Factors; Odds Ratio; Immunologic Factors; Humans; Multiple Sclerosis Relapsing-Remitting; Cognition; Italy; Risk Assessment; Adult; Treatment Outcome; Adolescent; Neuropsychological Tests; Male; Severity of Illness Index; Neurologic Examination; Interferon-beta; Predictive Value of Tests; Cognition Disorders; Cross-Sectional Studies; Intelligence; Prospective Studies; Risk Factors; Disability Evaluation; Middle Aged; Female; PrevalencemedicineHumansImmunologic FactorsExpanded Disability Status ScaleMultiple sclerosisMcDonald criteriaInterferon-betamedicine.diseaseCross-Sectional StudiesPhysical therapyNeurology (clinical)Cognition Disorders
researchProduct

Neurocognitive functioning in children with type-1 diabetes with and without episodes of severe hypoglycaemia

2007

Previous studies have shown that recurrent severe hypoglycaemia can cause long-term cognitive impairment in children with type-1 diabetes, but the results are controversial, possibly due to the heterogeneity of samples and lack of comprehensive neuropsychological assessments of children. The aim of this study was to assess the effects of diabetes and severe hypoglycaemia on the neurocognitive functioning of children with a standardized, wide age-range neuropsychological test battery designed for the assessment of children. Eleven children with diabetes and a history of severe hypoglycaemia, 10 children with diabetes without a history of severe hypoglycaemia, and 10 healthy control children …

MalePediatricsmedicine.medical_specialty030209 endocrinology & metabolismNeuropsychological TestsSeverity of Illness IndexNEPSYPerceptual Disorders03 medical and health sciences0302 clinical medicineDevelopmental Neuroscience030225 pediatricsmedicineHumansNeuropsychological assessmentChildPsychiatryPsychomotor learningLanguage Disordersmedicine.diagnostic_testNeuropsychologyWechsler Adult Intelligence ScaleNeuropsychological testExecutive functionsHypoglycemia3. Good healthDiabetes Mellitus Type 1Child PreschoolPediatrics Perinatology and Child HealthFemaleNeurology (clinical)Psychomotor DisordersCognition DisordersPsychologyNeurocognitive030217 neurology & neurosurgeryDevelopmental Medicine & Child Neurology
researchProduct

Childhood-onset CADASIL: clinical, imaging, and neurocognitive features.

2010

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is a progressive neurodegenerative condition, associated with mutations in the notch3 gene. Symptoms include migraine with aura, mood disorders, progressive cognitive decline, subcortical ischemic strokes, dementia, and premature death. We present an 8-year-old boy with attention and behavioral difficulties, as well as a family history of the condition. Magnetic resonance imaging revealed subcortical foci of increased T2 hyperintensity, and sequencing of the notch3 gene revealed 1 previously reported mutation and 1 novel sequence variant. Neurocognitive assessment revealed deficits in sever…

MalePediatricsmedicine.medical_specialtyCADASILNeuropsychological TestsLeukoencephalopathymedicineHumansClinical imagingAge of OnsetCADASILChildReceptor Notch3medicine.diagnostic_testReceptors NotchBrainGenetic VariationMagnetic resonance imagingSequence Analysis DNAmedicine.diseaseMagnetic Resonance ImagingPediatrics Perinatology and Child HealthMutationNeurology (clinical)Age of onsetPsychologyCognition DisordersNeuroscienceNeurocognitiveJournal of child neurology
researchProduct